Clinical Trials Browser

Interventional × PHI-101 × Clear all

NCT04678102 2023-06-26

CREATIVE

Phase 1 Unknown

Platinum-resistant Ovarian Cancer

NCT04842370 2021-04-20

Evaluation of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PHI 101 for the Treatment of AML

Phase 1 Unknown

Other hematologic neoplasm

Recurrence, Leukemia, Myeloid, Acute